chr6-43770989-G-T

Variant summary

Our verdict is Likely benign. The variant received -6 ACMG points: 0P and 6B. BP4_ModerateBS2

The NM_003376.6(VEGFA):​c.283G>T​(p.Gly95Trp) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000503 in 1,390,572 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★).

Frequency

Genomes: not found (cov: 33)
Exomes 𝑓: 0.0000050 ( 0 hom. )

Consequence

VEGFA
NM_003376.6 missense

Scores

2
4
11

Clinical Significance

Uncertain significance criteria provided, single submitter U:1

Conservation

PhyloP100: 2.14

Publications

0 publications found
Variant links:
Genes affected
VEGFA (HGNC:12680): (vascular endothelial growth factor A) This gene is a member of the PDGF/VEGF growth factor family. It encodes a heparin-binding protein, which exists as a disulfide-linked homodimer. This growth factor induces proliferation and migration of vascular endothelial cells, and is essential for both physiological and pathological angiogenesis. Disruption of this gene in mice resulted in abnormal embryonic blood vessel formation. This gene is upregulated in many known tumors and its expression is correlated with tumor stage and progression. Elevated levels of this protein are found in patients with POEMS syndrome, also known as Crow-Fukase syndrome. Allelic variants of this gene have been associated with microvascular complications of diabetes 1 (MVCD1) and atherosclerosis. Alternatively spliced transcript variants encoding different isoforms have been described. There is also evidence for alternative translation initiation from upstream non-AUG (CUG) codons resulting in additional isoforms. A recent study showed that a C-terminally extended isoform is produced by use of an alternative in-frame translation termination codon via a stop codon readthrough mechanism, and that this isoform is antiangiogenic. Expression of some isoforms derived from the AUG start codon is regulated by a small upstream open reading frame, which is located within an internal ribosome entry site. The levels of VEGF are increased during infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), thus promoting inflammation by facilitating recruitment of inflammatory cells, and by increasing the level of angiopoietin II (Ang II), one of two products of the SARS-CoV-2 binding target, angiotensin-converting enzyme 2 (ACE2). In turn, Ang II facilitates the elevation of VEGF, thus forming a vicious cycle in the release of inflammatory cytokines. [provided by RefSeq, Jun 2020]

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Likely_benign. The variant received -6 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.21134296).
BS2
High AC in GnomAdExome4 at 7 AD gene.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
VEGFANM_003376.6 linkc.283G>T p.Gly95Trp missense_variant Exon 1 of 8 ENST00000672860.3 NP_003367.4 P15692-13

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
VEGFAENST00000672860.3 linkc.283G>T p.Gly95Trp missense_variant Exon 1 of 8 NM_003376.6 ENSP00000500082.3 P15692-13A0A5F9ZH41

Frequencies

GnomAD3 genomes
Cov.:
33
GnomAD4 exome
AF:
0.00000503
AC:
7
AN:
1390572
Hom.:
0
Cov.:
36
AF XY:
0.00000583
AC XY:
4
AN XY:
685708
show subpopulations
African (AFR)
AF:
0.00
AC:
0
AN:
30594
American (AMR)
AF:
0.00
AC:
0
AN:
35242
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
24966
East Asian (EAS)
AF:
0.00
AC:
0
AN:
35052
South Asian (SAS)
AF:
0.00
AC:
0
AN:
78210
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
47980
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
4186
European-Non Finnish (NFE)
AF:
0.00000557
AC:
6
AN:
1076712
Other (OTH)
AF:
0.0000174
AC:
1
AN:
57630
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.554
Heterozygous variant carriers
0
1
2
2
3
4
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
Cov.:
33
Alfa
AF:
0.0000314
Hom.:
0

ClinVar

Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link

Submissions by phenotype

not provided Uncertain:1
May 01, 2016
CeGaT Center for Human Genetics Tuebingen
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Benign
-0.16
T
BayesDel_noAF
Benign
-0.47
CADD
Pathogenic
26
DANN
Uncertain
0.99
DEOGEN2
Benign
0.25
T;.;.;T;.;.;.;.;.;T;.;.;.;T;.
Eigen
Benign
0.17
Eigen_PC
Benign
0.15
FATHMM_MKL
Uncertain
0.87
D
LIST_S2
Uncertain
0.87
D;D;D;D;D;D;D;D;D;D;D;D;D;D;D
M_CAP
Pathogenic
0.29
D
MetaRNN
Benign
0.21
T;T;T;T;T;T;T;T;T;T;T;T;T;T;T
MetaSVM
Benign
-1.1
T
PhyloP100
2.1
PrimateAI
Pathogenic
0.80
T
PROVEAN
Benign
-0.81
N;.;N;N;.;.;.;.;.;N;N;.;N;N;N
REVEL
Benign
0.16
Sift
Benign
0.030
D;.;D;D;.;.;.;.;.;D;D;.;D;D;D
Sift4G
Uncertain
0.010
D;.;D;D;D;D;.;D;.;D;D;D;D;D;D
Polyphen
1.0, 0.93, 0.99, 0.99
.;.;.;.;D;P;.;D;D;.;.;.;.;.;.
MutPred
0.066
Loss of relative solvent accessibility (P = 0.0186);Loss of relative solvent accessibility (P = 0.0186);Loss of relative solvent accessibility (P = 0.0186);Loss of relative solvent accessibility (P = 0.0186);Loss of relative solvent accessibility (P = 0.0186);Loss of relative solvent accessibility (P = 0.0186);Loss of relative solvent accessibility (P = 0.0186);Loss of relative solvent accessibility (P = 0.0186);Loss of relative solvent accessibility (P = 0.0186);Loss of relative solvent accessibility (P = 0.0186);Loss of relative solvent accessibility (P = 0.0186);Loss of relative solvent accessibility (P = 0.0186);Loss of relative solvent accessibility (P = 0.0186);Loss of relative solvent accessibility (P = 0.0186);Loss of relative solvent accessibility (P = 0.0186);
MVP
0.45
ClinPred
0.88
D
GERP RS
3.0
PromoterAI
-0.12
Neutral
RBP_binding_hub_radar
1.1
RBP_regulation_power_radar
2.2
gMVP
0.048
Mutation Taster
=289/11
polymorphism

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs1582460373; hg19: chr6-43738726; API